




RealRate

PHARMACEUTICAL 2018

Anixa Biosciences Inc
Rank 213 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 134% points. The greatest weakness of Anixa Biosciences Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is -240%, being 38% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	7,014
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	889
Liabilities, Non-Current	0
Other Assets	1,746
Other Compr. Net Income	0
Other Expenses	930
Other Liabilities	0
Other Net Income	1,567
Property and Equipment	53
Research and Development	1,598
Revenues	362
Selling, General and Administrative Expense	4,411

Output Variable	Value in 1000 USD
Assets	8,812
Liabilities	889
Expenses	6,939
Stockholders Equity	7,923
Net Income	-5,009
Comprehensive Net Income	-5,009
Economic Capital Ratio	-240%